The introduction of angiotensin receptor neprilysin inhibitors (ARNI) was a major breakthrough in HF management, for the first time targeting the natriuretic peptide system in addition to the renin–angiotensin–aldosterone pathway to potentiate the effects of older drug classes. This evidence concerns the gene REN and hydrops fetalis.